---
title: "BridgeBio Pharma Says Acoramidis Reduces CVM Or CVH Risk By 49% Through Month 30"
description: "BridgeBio Pharma Inc :ACORAMIDIS BEGINS TO REDUCE CUMULATIVE CARDIOVASCULAR OUTCOMES WITHIN THE FIRST MONTH OF TREATMENT IN PATIENTS WITH ATTR-CMBRIDGEBIO PHARMA INC - ACORAMIDIS REDUCES CVM OR CVH RI"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/259221798.md"
published_at: "2025-09-28T15:18:56.000Z"
---

# BridgeBio Pharma Says Acoramidis Reduces CVM Or CVH Risk By 49% Through Month 30

> BridgeBio Pharma Inc :ACORAMIDIS BEGINS TO REDUCE CUMULATIVE CARDIOVASCULAR OUTCOMES WITHIN THE FIRST MONTH OF TREATMENT IN PATIENTS WITH ATTR-CMBRIDGEBIO PHARMA INC - ACORAMIDIS REDUCES CVM OR CVH RISK BY 49% THROUGH MONTH 30

BridgeBio Pharma Inc :

-   ACORAMIDIS BEGINS TO REDUCE CUMULATIVE CARDIOVASCULAR OUTCOMES WITHIN THE FIRST MONTH OF TREATMENT IN PATIENTS WITH ATTR-CM
-   BRIDGEBIO PHARMA INC - ACORAMIDIS REDUCES CVM OR CVH RISK BY 49% THROUGH MONTH 30

### Related Stocks

- [BBIO.US - Bridgebio Pharma](https://longbridge.com/en/quote/BBIO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BridgeBio Pharma (BBIO) Receives a Buy from TD Cowen | TD Cowen analyst Tyler Van Buren has maintained a Buy rating on BridgeBio Pharma (BBIO) with a price target of $95.00. V | [Link](https://longbridge.com/en/news/275790948.md) |
| BridgeBio Pharma Highlights Pipeline Progress and Patient Impact in New Corporate Presentation | BridgeBio Pharma Inc. has released a corporate presentation outlining its pipeline and strategy, focusing on first-in-cl | [Link](https://longbridge.com/en/news/272295165.md) |
| BridgeBio Pharma Highlights Attruby Surge, Preannounces $146M Q4 Revenue at JPM Healthcare Conference | BridgeBio Pharma (NASDAQ:BBIO) presented at the J.P. Morgan Healthcare Conference, highlighting its ATTR-CM product, Att | [Link](https://longbridge.com/en/news/272361328.md) |
| BridgeBio Pharma Publishes Study on Acoramidis for ATTR-CM | BridgeBio Pharma Inc. has published a study on acoramidis (Beyonttra) for treating transthyretin amyloid cardiomyopathy  | [Link](https://longbridge.com/en/news/265036749.md) |
| BridgeBio Pharma (BBIO) Valuation Check After Insider Selling And Upcoming Infigratinib Trial Updates | BridgeBio Pharma (BBIO) faces scrutiny as insider selling coincides with upcoming catalysts, including a January 9 webin | [Link](https://longbridge.com/en/news/271695155.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.